New directions in therapy for ocular allergy

International Ophthalmology Clinics

Volumn 36, Issue 2, 1996, Pages 25-44

  El Defrawy, Sherif ^b   Jackson, W Bruce ^a  

^a UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTAZOLINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CHLORPHENIRAMINE; CHLORPHENIRAMINE MALEATE; CLEMASTINE; CLEMASTINE FUMARATE; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DEXAMETHASONE; EMEDASTINE; FLUOROMETHOLONE; KETOROLAC; LEVOCABASTINE; LODOXAMIDE; LODOXAMIDE TROMETAMOL; LORATADINE; LOTEPREDNOL ETABONATE; NAPHAZOLINE; NEDOCROMIL; PENTAPEPTIDE; PHENIRAMINE; PREDNISOLONE; RIMEXOLONE; SUPROFEN; TERFENADINE;

ALLERGY; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; EYE DISEASE; HUMAN; MAST CELL DEGRANULATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0029910427     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199603620-00005     Document Type: Review

References (120)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-575
2. 2 on the eye. Invest Ophthalmol Vis Sci 1982;22(suppl):135
3. Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995;50:208-221
4. Abelson MB, Weston JH. Antihistamines. In: Lambert DW, Potter DE, eds. Clinical ophthalmic pharmacology. Boston: Little, Brown, 1987:417-424
5. Babe KS, Serafin WE. Histamine, bradykinin and their antagonists. In: Hardman J, Limbird L, eds. Goodman and Gilman's the pharmacological basis of therapeutics, ed 9. New York: McGraw Hill, 1996:581-600
6. Jaanus SD, Hegeman SL, Swanson MW. Antiallergy drugs and decongestants. In: Bartlett JD, Jaanus SD, eds. Clinical ocular pharmacology, ed 3. Toronto: Butterworth-Heinemann, 1995:345
7. Bussche GV, Emanuel MB, Rombaut N. Clinical profile of astemizole. A survey of 50 double-blind trials. Ann Allergy 1987;58:184-188
8. Masi M, Candiani R, van de Venn EH. A placebo-controlled trial of certirizine in seasonal allergic rhino-conjunctivitis in children aged 6-12 years. Pediatr Allergy Immunol 1993;(4 suppl):47-52
9. Ciprandi G, Buscagalia S, Marchesi E, et al. Protective effects of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Immunol 1993;100(2):185-189
10. 2-receptors in the human ocular surface. Arch Ophthalmol 1981;99:302-304
11. Mayumi H, Kimura S, Asano M, et al. Intravenous cimetidine as an effective treatment for systemic anaphylaxis and acute allergic skin reactions. Ann Allergy 1987;58:447-450
12. 1-receptors in the human ocular surface. Invest Ophthalmol Vis Sci 1981;20(suppl):32
13. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;38(suppl):115-132
14. Leon J, Charap A, Duzmen E, et al. Efficacy of cimetidine/pyrilamine eye drops, a dose response study with histamine challenge. Ophthalmology 1986;93:120-123
15. Sujar J, Nyberg M, Bernstein J, et al. Imipramine inhibition of ragweed allergic conjunctivitis. Invest Ophthalmol Vis Sci 1984;25:217-218
16. Berdy GJ, Abelson MB, George MA, et al. Allergic conjunctivitis: a survey of new antihistamines. J Ocul Pharmacol 1991;7:313-324
17. Reiss J, Abelson MB, George MA, et al. Allergic conjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular infections and immunity. St. Louis: Mosby, 1996:345-358
18. 1 antagonist in patients with allergic conjunctivitis. Allergy 1985;40:491-496
19. 1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test. Int Arch Allergy Appl Immunol 1987;82:541-543
20. Abelson MB, Smith LM. Levocabastine: evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 1988;95:1494-1497
21. Stokes TC, Feinberg GG. Rapid onset of levocabastine eye drops in histamine-induced conjunctivitis. Clin Exp Allergy 1993;23:791-794
22. Azevedo M, Castel-Branco MG, Oliveira JE, et al. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991;21:689-694
23. 1 antagonist and seasonal allergic rhino-conjunctivitis. Allergy 1987;42:512-515
24. Rimas M, Bjorkstein B, Kjellman N. Topical levocabastine protects better than sodium chromoglycate and placebo in conjunctival provocation tests. Allergy 1990;45:18-21
25. Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995;- 102:310-316
26. Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993;48:519-524
27. 1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994;10(4):653-664
28. 1 antagonist for topical ocular use. J Ocul Pharmacol 1994;10(4):665-675
29. Lowry GM, Abelson M, Rubin JM. Emedastine ophthalmic solution alleviates ocular itching and redness associated with allergic conjunctivitis. Invest Ophthalmol Vis Sci 1996;37(suppl):593
30. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol 1983;95:502-505
31. Meyer E, Kraus E, Zonis S. Efficacy of antiprostaglandin therapy in vernal conjunctivitis. Br J Ophthalmol 1987;71:497-499
32. Wood TS, Steward RH, Bowman RW, et al. Suprofen treatment of contact lensassociated giant papillary conjunctivitis. Ophthalmology 1988;95:822-826
33. Buckley DC, Caldwell DR, Reaves TA. Treatment of vernal conjunctivitis with suprofen, a topical non-steroidal antiinflammatory agent. Invest Ophthalmol Vis Sci 1986;27:29-37
34. Tinkelman D, Rupp G, Kaufman H, et al. Double-masked paired- comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution paired with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Surv Oph-thalmol 1993;38:133-140
35. Ballas Z, Blumenthal M, Tinkelman D. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:141-148
36. Jaanus SD, Lesher GA. Anti-inflammatory drugs. In: Bartlett JD, Jaanus SD, eds. Clinical ocular pharmacology, ed 3. Boston: Butterworth-Heinemann, 1995:303-335
37. Bartlett JD, Howes JE, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-321
38. Abelson M, George M, Drake M, et al. Evaluation of rimexolone ophthalmic suspension in the antigen challenge model of allergic conjunctivitis. Invest Ophthalmol Vis Sci 1992;33(suppl):2094
39. Foreman FC, Hallett MB, Mangar J. The relationship between histamine secretion and 45 calcium uptake by mast cells. J Physiol (Lond) 1977;271:193
40. Ishizaka T, White JR, Saito H. Activation of basophils and mast cells for mediator release. Int Arch Allergy Appl Immunol 1987;82:327-332
41. Rothenberg ME, Owen WF, Stevens RL. Mast cells and eosinophils. Int Ophthalmol Clin 1988;28:267-274
42. Schwanz LB. Mediators of human mast cells and human mast cell subsets. Ann Allergy 1987;58:226-237
43. Butrus SI, Irani AMA, Tabbara KF, et al. Increased number of T mast cells in vernal conjunctivitis. Presented at the Twenty-First Meeting of the Ocular Microbiology and Immunology Group, Dallas, TX, Nov 7, 1987
44. tc in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990;86:34-40
45. Bernstein JA, Lawrence ID. The mast cell: a comprehensive, updated review. Allergy Proc 1990;11:209
46. Berdy GJ, Abelson MB. Antihistamines and mast cell stabilizers in allergic ocular disease. In: Albert DM, Jakobiec FA, eds. Principles and practice of ophthalmology: basic sciences. Philadelphia: Saunders, 1994:1028-1042
47. Foreman JC, Garland LG. Cromoglycate and other anti-allergic drugs: a possible mechanism of action. Br Med J 1976;1:820-821
48. c-receptor mediated calcium influx and mediator secretion in rat mucosal mast cells. Biochemistry 1991;30:1523-1532
49. Kay AB, Walsh GM, Moqbel R, et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol 1987;80:1-8
50. Skedinger MC, Augustine NH, Morris EZ, et al. Effect of disodium cromoglycate on neutrophil movement and intracellular calcium mobilization. J Allergy Clin Immunol 1987;80:573-577
51. Gonzalez JP, Brogden RN. Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987;34:560-577
52. Bonini S, Schiavone M, et al. Lodoxamide inhibits mast cell degranulation and eosinophil recruitment in the tear film following conjunctival provocation test. Invest Ophthalmol Vis Sci 1996;37(suppl):S647
53. Foreman JC. Neuropeptides and the pathogenesis of allergy. Allergy 1987;42:1-11
54. Foreman JC. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int Arch Allergy Appl Immunol 1987;82:366-371
55. Dixon M, Jackson DM, Richards IM. The action of sodium cromoglycate on "C" fibre endings in the dog lung. Br J Pharmacol 1980;70:11-13
56. Friday GA, Biglan AW, Hills DA, et al. Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution. Am J Ophthalmol 1983;95:169-174
57. Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988;95:194-201
58. Foster CS, Duncan BA. Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis. Am J Ophthalmol 1980;90:175-181
59. Tabbara KF, Arafat NT. Cromolyn effects of vernal keratoconjunctivitis in children. Arch Ophthalmol 1977;95:2184-2186
60. Meisler DM, Berzins UJ, Krachmer JH, et al. Cromolyn treatment of giant papillary conjunctivitis. Arch Ophthalmol 1982;100:1608-1610
61. Jay JL. Clinical factors and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate. Br J Ophthalmol 1981;65:335-340
62. Johnson HG, VanHout CA, Wright JB. Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,585E:I. Activity in rats. Int Arch Allergy Appl Immunol 1978;56:416-423
63. Nyberg M, Sugar J, Fiscella R. Effect of lodoxamide tromethamine on immediate hypersensitivity in the guinea pig conjunctiva. Invest Ophthalmol Vis Sci 1984;25:27
64. Aoki KR, Jones MM, Robertson SM, et al. Topical antiallergic activity of lodoxamide against a passive anaphylaxis reaction in the rat conjunctiva. Invest Ophthalmol Vis Sci 1985;26:190
65. Verstappen AA, Smith J, Rosenthal A. A double-masked efficacy and safety evaluation of lodoxamide 0.1% ophthalmic solution versus opticrom 2%. A multicenter study in patients with allergic eye disorders. Alcon Report no. 008:34350:1287,1988
66. Caldwell DR, Verin P, et al. Efficacy and safety of lodoxamide 0.1% versus cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol 1992;113:632-637
67. Fahy G, Easty DL, Collum L, et al. Double masked efficacy and safety evaluation of lodoxamide 0.1% ophthalmic solution versus optichrom 2%. A multicentre study. Ophthalmol Today 1988:341-342
68. Cerqueti PM, Ricca V, Tosca MA, et al. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol 1994;105:185-189
69. Kjellman MI, Stevens MT. Clinical experience with Tilavist: an overview of efficacy and safety. Allergy 1995;50(21 suppl):14-22
70. Alexander M. Comparative therapeutic studies with Tilavist. Allergy 1995;50(21 suppl):23-39
71. Bailey CS, Buckley BJ. Nedocromil sodium in contact lens associated papillary conjunctivitis. Eye 1993;(suppl):29-33
72. Spitalny L, Abelson M. Olopatadine ophthalmic solution decreases itching and redness associated with allergic conjunctivitis. Invest Ophthalmol Vis Sci 1996;37(suppl):593
73. Hamburger RN. Peptide inhibition of the Prausnitz-Kustner reaction. Science 1975;189:389-390
74. Bennich H, Ragnarsson U, Johansson SGO, et al. Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and mast cells. Int Arch Allergy Appl Immunol 1977;53:459-468
75. Prenner BM. Double-blind placebo-controlled trial of intranasal IgE pentapeptide. Ann Allergy 1987;58:332-335
76. Abelson MB, Smith LM, George MA, et al. The efficacy of a new anti-allergic agent, Pentyde, in the allergen challenge model of allergic conjunctivitis. Invest Ophthalmol Vis Sci 1991;32(suppl):683
77. Floyd R, Kalpaxis J, Thayer T, et al. Double-blind comparison of HEPP (IgE pentapeptide) 0.5% ophthalmic solution (H) and sodium cromolyn ophthalmic solution, USP 4% (O) in patients having allergic conjunctivitis. Invest Ophthalmol Vis Sci 1988;29(suppl):45
78. Wyczolkowska J, Maslinski C. Inhibition by nicotinamide of an homologous PCA reaction and antigen-induced histamine release from rat peritoneal mast cells. Int Arch Allergy Appl Immunol 1975;49:285-292
79. Bekier E, Maslinski C. Antihistaminic action of nicotinamide. Agents Action 1974;4:196
80. Bekier E, Wyczolkowska J, Szych H, et al. The inhibitory effects of nicotinamide on asthma-like symptoms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice, and histamine release from rat peritoneal mast cells by compound 48/80. Int Arch Allergy Appl Immunol 1974;47:747-748
81. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130:753-758
82. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986;122:670-674
83. Bent S, Greven T, Braam U, et al. Effects of calmodulin antagonists on histamine release from human adenoidal mast cells. Arch Pharmacol 1989;339:R78
84. Gietzen K, Glatzel M, Gottried B. Effects of calmodulin antagonists on anaphylactoid reactions. Arch Pharmacol 1989;339:R49
85. Trocme SD, Aldave AJ. The eye and the eosinophil. Surv Ophthalmol 1994;39:241-252
86. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986;39:177-253
87. Moy JN, Gleich GJ, Thomas LL. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on Superoxide anion generation and lysosomal enzyme release. J Immunol 1990;145:2626-2632
88. Thomas LL, Zheutlin LM, Gleich GJ. Pharmacological control of human basophil histamine release stimulated by eosinophil granule major basic protein. Immunology 1989;66:611-615
89. Venge P, Hakansson L, Peterson CGB. Eosinophil activation in allergic disease. Int Arch Allergy Appl Immunol 1987;82:333-337
90. Trocme SD, Kephart GM, Allansmith MR, et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens associated giant papillary conjunctivitis. Am J Ophthalmol 1989;108:57-63
91. Trocme SD, Kephart GM, Bourne WM, et al. Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol 1993;115:640-643
92. Udell IJ, Gleich GJ, Allansmith MR, et al. Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears. Am J Ophthalmol 1981;92:824-828
93. Trocme SD, Kephart GM, Bourne WM, et al. Eosinophil granule major basic protein in contact lenses of patients with giant papillary conjunctivitis. CLAO J 1990;16:219-222
94. Capron M. Eosinophils: receptors and mediators in hypersensitivity. Clin Exp Allergy 1989;19(suppl):3-8
95. Prin L, Capron M, Tonnel A-B, et al. Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol 1983;72:336-346
96. Fadal RG. Immunotherapy failure. Otolaryngol Clin North Am 1985;18:805-819
97. Frostad AB, Grimmer O, Sandvik L, et al. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively. Clin Allergy 1983;13:337-357
98. Perelmutter L. IgE regulation during immunotherapy of allergic diseases. Ann Allergy 1986;57:78-85
99. Geha RS. Idiotypic interaction in the treatment of human diseases. Adv Immunol 1986;39:255-297
100. Leung DYM, Rhodes AR, Geha RS. Atopic dermatitis. In: Fitzpatrick TB, Elsen AZ, Wolff K, et al, eds. Dermatology in general medicine. New York: McGraw-Hill, 1987:1385-1408
101. Rocklin RE, Sheffer AL, Greineder DK, et al. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-1219
102. Bjorksten B, Moller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986;41:290-295
103. Moller C, Dreborg S, Lanner A, et al. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986;41:271-279
104. Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization. Allergy 1985;40:321-335
105. Rebien W, Puttonen E, Maasch JH, et al. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatr 1982;138:341-344
106. Lowenstein H, Mygind N. Extraction and degradation of Timothy pollen allergen during simulated in vivo conditions. Allergy 1978;33:238-240
107. Del Prete A, Loffredo C, Carderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Ophthalmologica 1994;72:631-634
108. Conner J, Sullivan S, Juang L. Monoclonal antibody and liposomes. Pharmacol Ther 1985;28:341-365
109. Faulds D, Goa KL, Benfield P. Cyclosporin, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040
110. BenEzra D, Pe'er J, Brodsky M, et al. Cyclosporine eye-drops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986;101:278-282
111. Bleik JH, Khalid F, Tabbara F. Topical cyclosporin in vernal keratoconjunctivitis. Ophthalmology 1991;98:1679-1684
112. Foster CS, Calong N. Atopic keratoconjunctivitis. Ophthalmology 1992;97:992-1000
113. Abu El-Asrar AM, Tabbara KF, Geboes K, et al. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol 1996;121:156-161
114. Geha RS, Helm B, Gould H. Inhibition of the Prausnitz-Kustner reaction by an immunoglobulin E-chain fragment synthesized in E. coli. Nature 1985;315:577-578
115. Geha RS, Leung DYM. Regulation of the human allergic response. Int Arch Allergy Appl Immunol 1987;82:389-391
116. Gould HJ, Helm BA, Marsh PJ, et al. Recombinant human IgE. Int Arch Allergy Appl Immunol 1987;82:392-393
117. Tabbara KF, Abu El-Asrar AM, Geboes K, et al. Adhesion molecules in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 1996;37(suppl):4695
118. Ciprandi G, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993;91:783-792
119. Lee VHL, Urrea PT, Smith RE, et al. Ocular drug bioavailability from topically applied liposomes. Surv Ophthalmol 1985;29:335-348
120. Guo LSS, Sarris AM, Levy MD. A safe bioadhesive liposomal formulation for ophthalmic applications. Invest Ophthalmol Vis Sci 1988;29(suppl):439